Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...
Eli Lilly's Mounjaro and Zepbound deliver accelerated weight loss rates compared to Novo Nordisk's Wegovy. Learn why LLY ...
NBC News' Tom Llamas talks to CEO of Eli Lilly David Ricks about the company's new deal with the Trump administration to cut ...
Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...
Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.
A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site ...
The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.
COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its ...
The monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage ...
A new weight-loss drug from Eli Lilly & Co. helped patients shed as much weight as popular shots like Zepbound, giving the company another edge in the fast-growing obesity market.
Competition is working, even as the FTC meddles in a takeover fight in a way that helped Pfizer.
Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.